CDK2 activation in mouse epidermis induces keratinocyte proliferation but does not affect skin tumor development

American Journal of Pathology

Volumn 173, Issue 2, 2008, Pages 526-535

  Macias, Everardo ^a,f   Miliani De Marval, Paula L ^b   De Siervi, Adriana ^c   Conti, Claudio J ^d   Senderowicz, Adrian M ^c,e   Rodriguez Puebla, Marcelo L ^a  

^a NORTH CAROLINA STATE UNIVERSITY   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c NATIONAL INSTITUTE OF DENTAL AND CRANIOFACIAL RESEARCH   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^f UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE INHIBITOR 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME BINDING; EPIDERMIS; HOMEOSTASIS; KERATINOCYTE; MOUSE; NEWBORN; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKIN CARCINOGENESIS; SKIN TUMOR; TRANSGENIC MOUSE;

EID: 48749133336     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.071124     Document Type: Article

References (51)

1. Sherr CJ: D-type cyclins. Trends Biochem Sci 1995, 20:187-190
2. Weinberg RA: The retinoblastoma protein and cell cycle control. Cell 1995, 81:323-330
3. Blain S, Montalvo E, Massague J: Differential interaction of the cyclin-dependent kinase (cdk) inhibitor p27Kip1 with cyclin A-cdk2 and cyclin D2-cdk4. J Biol Chem 1997, 272:25863-25872
4. Labaer J, Garret MD, Stevenson LF, Slingerland JM, Sandhu C, Chou HS, Fattaey A, Harlow E: New functional activities for the p21 family of CDK inhibitors. Genes Dev 1997, 11:847-862
5. Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, Reed S, Sicinski P, Bartek J, Eilers M: Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J 1999, 18:5321-5333
6. Perez-Roger I, Kim SH, Griffiths B, Sewing A, Land H: Cyclins D1 and D2 mediate myc-induced proliferation via sequestration of p27(Kip1) and p21(Cip1). EMBO J 1999, 18:5310-5320
7. Miliani de Marval P, Gimenez-Conti I, LaCava M, Martinez L, Conti C, Rodriguez-Puebla M: Transgenic expression of CDK4 results in epidermal hyperplasia and severe dermal fibrosis. Am J Pathol 2001, 159:369-379
8. van den Heuvel S, Harlow E: Distinct roles for cyclin-dependent kinases in cell cycle control. Science 1993, 262:2050-2054
9. Ohtsubo M, Theodoras A, Schumacher J, Roberts J, Pagano M: Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. Mol Cell Biol 1995, 15:1559-1571
10. Pagano M, Pepperkok R, Verde F, Ansorge W, Draetta G: Cyclin A is required at two points in the human cell cycle. EMBO J 1992, 11:961-971
11. Tsai LH, Lees E, Faha B, Harlow E, Riabowol K: The cdk2 kinase is required for the G1-to-S transition in mammalian cells. Oncogene 1993, 8:1593-1602
12. Berthet C, Aleem E, Coppola V, Tassarollo L, Kaldis P: Cdk2 knockout mice are viable. Curr Biol 2003, 13:1775-1785
13. Ortega S, Prieto I, Odajima J, Martin A, Dubus P, Sotillo R, Barbero JL, Malumbres M, Barbacid M: Cyclin-dependent kinase 2 is essential for meiosis but not for mitotic cell division in mice. Nat Genet 2003, 35:25-31
14. Martín A, Odajima J, Hunt SL, Dubus P, Ortega S, Malumbres M, Barbacid M: Cdk2 is dispensable for cell cycle inhibition and tumor suppression mediated by p27(Kip1) and p21(Cip1). Cancer Cell 2005, 7:591-598
15. Marone M, Scambia G, Giannitelli C, Ferrandina G, Masciullo V, Bellacosa A, Benedetti-Panici P, Mancuso S: Analysis of cyclin E and CDK2 in ovarian cancer: gene amplification and RNA overexpression. Int J Cancer 1998, 75:34-39
16. Kitahara K, Yasui W, Kuniyasu H, Yokozaki H, Akama Y, Yunotani S, Hisatsugu T, Tahara E: Concurrent amplification of cyclin E and CDK2 genes in colorectal carcinomas. Int J Cancer 1995, 62:25-28
17. Shintani S, Mihara M, Nakahara Y, Kiyota A, Ueyama Y, Matsumura T, Wong DT: Expression of cell cycle control proteins in normal epithelium, premalignant and malignant lesions of oral cavity. Oral Oncol 2002, 38:235-243
18. Akama Y, Yasui W, Yokozaki H, Kuniyasu H, Kitahara K, Ishikawa T, Tahara E: Frequent amplification of the cyclin E gene in human gastric carcinomas. Jpn J Cancer Res 1995, 86:617-621
19. Keyomarsi K, Herliczek T: The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res 1997, 3:171-191
20. Eguchi N, Fujii K, Tsuchida A, Yamamoto S, Sasaki T, Kajiyama G: Cyclin E overexpression in human gallbladder carcinomas. Oncol Rep 1999, 6:93-96
21. Kiyokawa H, Kineman R, Manova-Todorova K, Soares V, Hoffman E, Ono M, Khanam D, Hayday A, Frohman L, Koff A: Enhanced growth of mice lacking the cyclin-dependent kinase inhibitor function of p27(Kip1). Cell 1996, 85:721-732
22. Nakayama K, Ishida N, Shirane M, Inomata A, Inoue T, Shishido N, Horii I, Loh DY: Mice lacking p27Kip1 display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. Cell 1996, 85:707-720
23. Fero ML, Rivkin M, Tasch M, Porter P, Carow CE, Firpo E, Polyak K, Tsai LH, Broudy V, Perlmutter RM, Kaushansky K, Roberts JM: A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. Cell 1996, 85:733-744
24. Gray-Bablin J, Zalvide J, Fox M, Knickerbocker C, DeCaprio J, Keyomarsi K: Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci USA 1996, 93:15215-15220
25. Harwell RM, Porter DC, Danes C, Keyomarsi K: Processing of cyclin E differs between normal and tumor breast cells. Cancer Res 2000, 60:481-489
26. Keyomarsi K, Conte DJ, Toyofuku W, Fox M: Deregulation of cyclin E in breast cancer. Oncogene 1995, 11:941-950
27. Corsino P, Davis B, Law M, Chytil A, Forrester E, Norgaard P, Teoh N, Law B: Tumors initiated by constitutive Cdk2 activation exhibit transforming growth factor beta resistance and acquire paracrine mitogenic stimulation during progression. Cancer Res 2007, 67:3135-3144
28. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV: Mammary hyperplasia and carcinoma in MMTV-cyclin D1 transgenic mice. Nature 1994, 369:669-671
29. Miliani de Marval PL, Macias E, Conti CJ, Rodriguez-Puebla ML: Enhanced malignant tumorigenesis in Cdk4 transgenic mice. Oncogene 2004, 23:1863-1873
30. Miliani de Marval PL, Macias E, Rounbehler R, Sicinski P, Kiyokawa H, Johnson DG, Conti CJ, Rodriguez-Puebla ML: Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues. Mol Cell Biol 2004, 24:7538-7547
31. Macias E, Kim Y, Miliani de Marval PL, Klein-Szanto A, Rodriguez-Puebla ML: Cdk2 deficiency decreases ras/CDK4-dependent malignant progression, but not myc-induced tumorigenesis. Cancer Res 2007, 67:9713-9720
32. Pierce AM, Gimenez-Conti IB, Schneider-Broussard R, Martinez LA, Conti CJ, Johnson DG: Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc Natl Acad Sci USA 1998, 95:8858-8863
33. Ramírez A, Bravo A, Jorcano J, Vidal M: Sequences 5′ of the bovine keratin 5 gene direct tissue- and cell-type-specific expression of a lacZ gene in the adult and during development. Differentiation 1994, 58:53-64
34. Minella AC, Swanger J, Bryant E, Welcker M, Hwang H, Clurman BE: p53 and p21 form an inducible barrier that protects cells against cyclin E-cdk2 deregulation. Curr Biol 2002, 12:1817-1827
35. He G, Siddik ZH, Huang Z, Wang R, Koomen J, Kobayashi R, Khokhar AR, Kuang J: Induction of p21 by p53 following DNA damage inhibits both Cdk4 and Cdk2 activities. Oncogene 2005, 24:2929-2943
36. Segawa K, Hokuto I, Minowa A, Ohyama K, Takano T: Cyclin E enhances P53-mediated transactivation. FEBS Lett 1993, 329:283-286
37. Quintanilla M, Brown K, Ramsden M, Balmain A: Carcinogen-specific mutation and amplification of Ha-ras during mouse skin carcinogenesis. Nature 1986, 322:78-80
38. Wunder JS, Eppert K, Burrow SR, Gokgoz N, Bell RS, Andrulis IL: Co-amplification and overexpression of CDK4. SAS and MDM2 occurs frequently in human parosteal osteosarcomas. Oncogene 1999, 18:783-788
39. Wei G, Lonardo F, Ueda T, Kim T, Huvos AG, Healey JH, Ladanyi M: CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons. Int J Cancer 1999, 80:199-204
40. Nikitakis N, Drachenberg C, Papadimitriou J: MDM2 and CDK4 expression in carcinosarcoma of the esophagus: comparison with squamous cell carcinoma. Exp Mol Pathol 2002, 73:198-208
41. Khatib Z, Matsushime H, Valentine M: Coamplification of the Cdk4 gene with MDM2 and GL1 in human sarcomas. Cancer Res 1993, 53:5535-5541
42. Dei Tos A, Doglioni C, Piccini S, Sciot R, Furlanetto A, Boiocchi M, Dal Cin P, Maestro R, Fletcher C, Tallini G: Coordinate expression and amplification of the MDM2. CDK4, and HMGI-C genes in atypical lipomatous tumours. J Pathol 2000, 190:531-536
43. Zuo L: Germline mutation in the p16Ink4a binding domain of cdk4 in familial melanoma. Nat Genet 1996, 12:97-99
44. Harwell RM, Mull BB, Porter DC, Keyomarsi K: Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem 2004, 279:12695-12705
45. Sherr CJ, Roberts JM: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 1999, 13:1501-12
46. McConnell B, Gregory F, Stott F, Hara E, Peters G: Induced expression of p16Ink4a inhibits both CDK4- and CDK2-associated kinase activity by reassortment of cyclin-CDK-inhibitor complexes. Mol Cell Biol 1999, 19:1981-1989
47. Tetsu O, McCormick F: Proliferation of cancer cells despite CDK2 inhibition. Cancer Cell 2003, 3:233-245
48. Lazarov M, Kubo Y, Cai T, Dajee M, Tarutani M, Lin Q, Fang M, Tao S, Green C, Kharavi P: CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 2002, 8:1105-1114
49. Morris RJ, Fischer SM, Slaga TJ: Evidence that a slowly cycling subpopulation of adult murine epidermal cells retains carcinogen. Cancer Res 1986, 46:3061-3066
50. Loeb KR, Kostner H, Firpo E, Norwood T, Tsuchiya D, Clurman BE, Roberts JM: A mouse model for cyclin E-dependent genetic instability and tumorigenesis. Cancer Cell 2005, 8:35-47
51. Minella AC, Grim JE, Welcker M, Clurman BE: p53 and SCFFbw7 cooperatively restrain cyclin E-associated genome instability. Oncogene 2007, 26:6948-6953